Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

Ladenburg Thalmann Healthcare Conference

Posted by fidest press agency su venerdì, 20 settembre 2019

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the 2019 Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 10:30am ET in New York, NY.
Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY).

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: